Congenital Hepatic Fibrosis Medication
- Author: Hisham Nazer, MB, BCh, FRCP, , DTM&H; Chief Editor: Carmen Cuffari, MD more...
No specific medical therapy is available for congenital hepatic fibrosis (CHF). The child's condition is usually stable, with liver enzyme levels within the reference range.
Antibiotic therapy is indicated for acute and recurrent cholangitis and is based essentially on the results of culture.
Reported to be an effective therapy in cholangitis that complicates CHF. Efficacy is attributed to high concentration in bile and hepatic parenchyma. Also has good in vitro activity against Enterobacteriaceae.
These agents enhance bile salt–dependent biliary flow. These may prove to be a valuable addition to therapy in repeated and refractory cholangitis.
Also called ursodeoxycholic acid. Has been shown to promote bile flow in cholestatic conditions associated with a patent extrahepatic biliary system.
These agents are used in medical management of portal hypertension. They reduce portal pressure through vasoconstriction of the mesenteric arterioles and reduce inflow to the portal venous system and portosystemic collaterals.
Decreases portal pressure in portal hypertension through vasoconstriction of the splanchnic arterioles thus controlling hemorrhage. Coronary artery disease is a notable undesirable effect. It may dispose patients with coronary artery disease to cardiac ischemia. This may be prevented with concurrent use of nitrates.
Has vasopressor and ADH activity. Increases water resorption at distal renal tubular epithelium (ADH effect) and promotes smooth muscle contraction throughout vascular bed of renal tubular epithelium.
Glypressin, triglycyl lysine vasopressin, can also be used in a dose of up to 2 mg IV q6h.
Not available in United States. Diminishes blood flow to portal system because of vasoconstriction, thus decreasing variceal bleeding. Has similar effects as vasopressin but does not cause coronary vasoconstriction.
Beta-blocker that lowers heart rate, myocardial contractility, cardiac output, and portal hypertension, thus reducing the risk of bleeding. Additionally, prevents increases in portal pressure (hepatic venous pressure gradient) during physical exertion.
Both propranolol and nadolol, beta-blockers, are effective in preventing first bleeding and reducing the mortality rate associated with bleeding.
Lipschitz B, Berdon WE, Defelice AR, Levy J. Association of congenital hepatic fibrosis with autosomal dominant polycystic kidney disease. Report of a family with review of literature. Pediatr Radiol. 1993. 23(2):131-3. [Medline].
Hoyer PF. Clinical manifestations of autosomal recessive polycystic kidney disease. Curr Opin Pediatr. 2015 Apr. 27 (2):186-92. [Medline].
Bristowe F. Cystic disease of the liver associated with similar disease of the kidney. Trans Pathol Soc Lond. 1856. 5:229.
Kerr DN, Harrison CV, Sherlock S, Walker RM. Congenital hepatic fibrosis. Q J Med. 1961 Jan. 30:91-117. [Medline].
O'Brien K, Font-Montgomery E, Lukose L, Bryant J, Piwnica-Worms K, Edwards H, et al. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012 Jan. 54 (1):83-9. [Medline].
Akhan O, Karaosmanoglu AD, Ergen B. Imaging findings in congenital hepatic fibrosis. Eur J Radiol. 2007 Jan. 61(1):18-24. [Medline].
Desmet VJ. Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation". Hepatology. 1992 Oct. 16(4):1069-83. [Medline].
Harris PC, Rossetti S. Molecular genetics of autosomal recessive polycystic kidney disease. Mol Genet Metab. 2004 Feb. 81(2):75-85. [Medline].
Losekoot M, Haarloo C, Ruivenkamp C, et al. Analysis of missense variants in the PKHD1-gene in patients with autosomal recessive polycystic kidney disease (ARPKD). Hum Genet. 2005 Nov. 118(2):185-206. [Medline].
Turkbey B, Ocak I, Daryanani K,et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol. 2009 Feb. 39(2):100-11. [Medline].
Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014 Sep. 134 (3):e833-45. [Medline].
El-Youssef M, Mu Y, Huang L, et al. Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr. 1999 Apr. 28(4):386-92. [Medline].
Ozaki S, Sato Y, Yasoshima M, et al. Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis. Liver Int. 2005 Aug. 25(4):817-28. [Medline].
Abdullah AM, Nazer H, Atiyeh M, Ali MA. Congenital hepatic fibrosis in Saudi Arabia. J Trop Pediatr. 1991 Oct. 37(5):240-3. [Medline].
Ovchinsky N, Moreira RK, Lefkowitch JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol. 2012 Jul. 19 (4):250-62. [Medline].
Al-Lawati TT. Fibropolycystic disease of the liver and kidney in Oman. Arab J Gastroenterol. 2013 Dec. 14 (4):173-5. [Medline].
Arikan C, Ozgenc F, Akman SA, et al. Impact of liver transplantation on renal function of patients with congenital hepatic fibrosis associated with autosomal recessive polycystic kidney disease. Pediatr Transplant. 2004 Dec. 8(6):558-60. [Medline].
Dagli U, Atalay F, Sasmaz N, et al. Caroli's disease: 1977-1995 experiences. Eur J Gastroenterol Hepatol. 1998 Feb. 10(2):109-12. [Medline].
Al-Bhalal L, Akhtar M. Molecular basis of autosomal recessive polycystic kidney disease (ARPKD). Adv Anat Pathol. 2008 Jan. 15(1):54-8. [Medline].
Ananthakrishnan AN, Saeian K. Caroli's disease: identification and treatment strategy. Curr Gastroenterol Rep. 2007 Apr. 9(2):151-5. [Medline].
Braga AC, Calheno A, Rocha H, Lourenco-Gomes J. Caroli's disease with congenital hepatic fibrosis and medullary sponge kidney. J Pediatr Gastroenterol Nutr. 1994 Nov. 19(4):464-7. [Medline].
Brancatelli G, Federle MP, Vilgrain V, et al. Fibropolycystic liver disease: CT and MR imaging findings. Radiographics. 2005 May-Jun. 25(3):659-70. [Medline].
Gocmen R, Akhan O, Talim B. Congenital absence of the portal vein associated with congenital hepatic fibrosis. Pediatr Radiol. 2007 Sep. 37(9):920-4. [Medline].
Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, Choyke P. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology. 2013 Jan. 144(1):112-121.e2. [Medline].
Gunay-Aygun M, Tuchman M, Font-Montgomery E, et al. PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. Mol Genet Metab. 2010 Feb. 99(2):160-73. [Medline].
Ling SC. Congenital cholestatic syndromes: what happens when children grow up?. Can J Gastroenterol. 2007 Nov. 21(11):743-51. [Medline].
McEvoy CF, Suchy FJ. Biliary tract disease in children. Pediatr Clin North Am. 1996 Feb. 43(1):75-98. [Medline].
Miller WJ, Sechtin AG, Campbell WL, Pieters PC. Imaging findings in Caroli's disease. AJR Am J Roentgenol. 1995 Aug. 165(2):333-7. [Medline].
Nakanuma Y, Harada K, Sato Y, Ikeda H. Recent progress in the etiopathogenesis of pediatric biliary disease, particularly Caroli's disease with congenital hepatic fibrosis and biliary atresia. Histol Histopathol. 2010 Feb. 25(2):223-35. [Medline].
Nazer D, Nazer H. Congenital Hepatic Fibrosis. Elzouki, Harfi, Nazer, Stapleton, et al. Textbook of Clinical Pediatrics. 2nd. Berlin-Heidelberg: Springer-Verlag; 2012. 3: 2013-16; Chapter 208.
Poala SB, Bisogno G, Colombatti R. Thrombocytopenia and splenomegaly: an unusual presentation of congenital hepatic fibrosis. Orphanet J Rare Dis. 2010. 5:4. [Medline].
Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012 May. 54(5):580-7. [Medline].
Suchy FJ. Liver disease in children. Mosby Yearbook. St Louis, MO: Mosby Year Book Inc; 1994.
Yonem O, Ozkayar N, Balkanci F, et al. Is congenital hepatic fibrosis a pure liver disease?. Am J Gastroenterol. 2006 Jun. 101(6):1253-9. [Medline].